Biotechnology/Pharmaceutical Opportunities in Canada

An Expert's View about Pharmaceuticals in Canada

Posted on: 4 Oct 2010

Canada maintains 668 biotechnology firms, considered second in the world in terms of number of companies. Canadian companies and research organisations are attractive in ternational business partners.

Sector briefing Biotechnology/Pharmaceutical Opportunities in Canada NB: Latest available figures used Why Canada? Canada maintains 668 biotechnology firms, considered second in the world in terms of number of companies. Ninety percent are SMEs and generate 4% of global biotech revenues. Firms are present across the country, including Western Canada (Alberta, British Columbia) 38%, Ontario 26%, Quebec 20%, Atlantic (New Brunswick, Newfoundland, Prince Edward Island) 10%, Prairies 1 (Saskatchewan, Manitoba) 6% . In 2009, spending on prescription drugs amounted to CAD$25.4B (£16.4B) and non- prescription drugs amounted to CAD$4.6B (£3B), an overall increase of 5.1% from 2009. ?Canada maintains 668 It is estimated that 54% of prescription drugs 2 biotechnology firms, purchased was generic drugs . considered second in the world in terms of number of Find general information on the Canadian companies.? market conditions on the UKTI Website. The Doing Business in Canada Guide gives an overview of Canada?s economy, business culture, potential opportunities and an introduction to other relevant issue. 1 ?Punching above its weight?, Biotech Canada Insights, Spring 2010 2 ?Growth in drug spending is slowing, CIHI reports?, The Globe and Mail, 23 April 2010 UK Trade & Investment Sector briefing: Biotechnology/Pharmaceutical Opportunities in Canada programme. The strategy set out to stimulate Opportunities the development of a critical mass of research infrastructure, large pools of post-graduate and A concerted effort by academia, industry, post-doctoral research, world-class academic, government, associations and the financial public and private sector research community has helped Canada become a world investigators, entrepreneurs and a biotech leader in biotechnology. Canadian companies sector vision. and research organisations are attractive international business partners as the country Established in 1992, The Networks of Centres is well-placed to provide access to other NAFTA 7 of Excellence (NCE) programme links markets. Canada currently has 301 health academic and industry researchers. Since biotech products in the pipeline and 60 1994, the nine biotechnology NCEs have spun- therapeutic medicines on the Canadian market 3 out 40 new companies to commercialise as a result of R&D in Canada . technologies. The federal government provides 8 CAD$77.4M (£50M) of funding each year . UK firms GSK and AstraZeneca maintain significant presence in Canada. In 2007, GSK The Scientific Research and Experimental invested CAD$178M (£116M) in R&D and Development (SR&ED) programme is a federal maintains facilities in Quebec, Ontario, Alberta, initiative offered to Canadian controlled firms 4 British Columbia, and Nova Scotia . pursing scientific research. Firms can apply to AstraZeneca maintains operations in Ontario tax credits against wages, materials, and an R&D centre in Quebec and invests machinery, equipment, some overhead, and 5 CAD$2M (£1.3M) per week on research . SR&ED contracts. These firms can claim a tax credit of 35% up to the first CAD$2M (£1.3M) R&D and Technology Transfer of qualifying expenditure, and 20% of any Canada has recognised that strong scientific excess. Research must be undertaken in 9 expertise and continuous investment in R&D Canada . are key factors to growth in the industry. Governments at all levels have invested in a In May 2010 the government announced the supportive infrastructure for the industry. first group of 20 Canada Excellence Research Chairs. This programme awards up to Canadian firms have strong linkages with CAD$10M (£6.5M) over seven years to each leading research and academic institutions and chairholder and their research team. One of access to public funding opportunities for the four priority research areas for this research conducted in Canada. Partnerships programme is health and related life 10 between UK and Canadian firms and academic sciences . institutions can be used to leverage these opportunities. Commercialisation Opportunities for UK professional services In 2007, R&D spend amounted to CAD$1.3B companies that offers consultancy in (£0.84B). The research community is commercialisation of R&D, proprietary comprised of approximately 30,000 people consultancy, technology licensing, technology based from 17 medical schools and more than transfer, joint ventures and project financing to 6 100 teaching hospitals . In addition, a series bridge the gap between the critical areas of of funding programmes and tax credits offer academia, research and commerce. support for the industry. Some examples are noted below. Production and trials International production and marketing In 1983, the federal government developed a partners, as well as clinical research national biotechnology strategy and established the National Research Council?s biotechnology 7 Networks of Centres of Excellence www.nce.gc.ca 3 8 ?Punching above its weight?, Biotech Canada Insights, Invest in Canadian Life Science ? R&D Infrastructure and Spring 2010 Government Resources, Industry Canada, accessed August 4 2009 Invest in Canada Biopharmaceuticals 2009 9 http://investincanada.gc.ca/download/833.pdf Invest in Canadian Life Science ? R&D Infrastructure and 5 AstraZeneca Canada site Government Resources, Industry Canada, accessed August www.astrazeneca.ca/en/aboutus/, accessed August 2010 2009 6 10 2009 Invest in Canada Biopharmaceuticals Canada Excellence Research Chairs www.cerc.gc.ca/hp- http://investincanada.gc.ca/download/833.pdf pa-eng.shtml UK Trade & Investment Sector briefing: Biotechnology/Pharmaceutical Opportunities in Canada organisations that are able to design and AstraZeneca Canada and Merck Frosst 12 undertake clinical trials in the UK for Canadian Canada . pharmaceutical firms. British Columbia: Industry strengths include Non-health biopharmaceutical and biomedical. Support Opportunities in non-health biotech also exist infrastructure includes the University of British predominantly in agri-bio applications such as Columbia, the BC Cancer Agency, and the BC food and crop sciences, marine, environmental Centres for Disease Control. bio-applications and renewable energy. There are currently 216 companies in the field of Other clusters: Canada?s vast and differing industrial and environmental biotechnology geography has also influenced the biotech engaged in efforts of advanced manufacturing, industry. Agri-bio clusters are located in the alternative energy and sustainable Prairie Provinces (Alberta, Saskatchewan, biomaterials. There are currently 165 Manitoba), while aquaculture and marine companies engaged in agriculture sciences clusters are located in Atlantic Canada 11 biotechnology . and the Pacific coast of British Columbia. Industry Clusters Biotechnology and pharmaceutical clusters are found throughout the country. Key hubs include: Ontario: Industry strengths include bioinformatics, genomics, biomaterials, biomedical engineering, stem cells and regenerative medicines, drug discovery, medical devices, agricultural biotechnology, bioproducts, functional foods and nutraceuticals. The province has more numerous renowned research centres and researchers, including the MaRS Discovery District in Toronto and The National Research Council (headquartered in Ottawa with branches throughout the country). Established in 2000, MaRS fosters commercialisation from scientific innovation. MaRS is a partnership between universities, hospital researchers, business and finance. It is also home to the Ontario Genomics Institute. Quebec: Industry strengths include genomics, biopharmaceuticals, bioinformatics, medical technologies, manufacturing, clinical research, and hosts research institutes such as Genome Quebec Innovation Centre and McGill University. In 2008, the province announced the creation of a public-private consortium in order to accelerate drug development, and develop safer and more effective drugs. The Consortium for Drug Discovery consists of an alliance between federal and Quebec government agencies, and Pfizer Canada, 11 12 ?Punching above its weight?, Biotech Canada Insights, Drug development boosted in Quebec, The Gazette Spring 2010 (Montreal), 18 June 2008 UK Trade & Investment Sector briefing: Biotechnology/Pharmaceutical Opportunities in Canada Major events and activities UKTI contacts BioContact Gilda Carbone www.biocontact.qc.ca Trade Officer British Consulate-General BioFinance Toronto, Canada www.biofinance.ca Tel: (001) 416 593 1290 ext 1+2224 Email: Gilda.Carbone@fco.gov.uk BioPartnering North America Web: www.ukti.gov.uk www.techvision.com/bpn/ Mathieu Blandford BIO International Convention Trade Associate www.bio.org British Consulate-General NB: Location differs throughout North America Toronto, Canada each year. A significant Canadian presence Tel: (001) 416 593 1290 ext 1+2257 participates in this key industry event. Email: Mathieu.Blandford@fco.gov.uk Web: www.ukti.gov.uk Find full details of all events in this country and sector on the UKTI website. New export events are added daily to the site and you can register to be alerted to them on a daily, weekly or monthly basis UKTI?s Tradeshow Access Programme (TAP) provides grant support for eligible Small & Medium Sized Enterprises (SME's) to attend trade shows overseas. Find out more about UKTI support for attendance at overseas events UK Trade & Investment Sector briefing: Biotechnology/Pharmaceutical Opportunities in Canada Next steps - How UKTI can help ? Arranging appointments British companies wishing to develop their ? Organise seminars or other events for you business in the Canadian market are advised to to meet contacts and promote your undertake as much market research and company in the Chinese market planning as possible in the UK. UKTI?s team in Canada with its wide local knowledge and This work is available via our Overseas Market experience, can provide a range of services to Introduction Service (OMIS) a chargeable British-based companies wishing to grow their service which assists British-based companies business in global markets. wishing to enter or expand their business in overseas markets. This can include: ? Provision of market information To find out more about commissioning this ? Validated lists of agents/distributors work, or accessing other UKTI services and ? Key market players or potential customers specialist advice, please visit the UKTI website in the Canadian market to find contact details for your local UKTI ? Establishment of interest of such contacts office. in working with you Whereas every effort has been made to ensure that the information given in this document is accurate, neither UK Trade & Investment nor its parent Departments (the Department for Business, Innovation & Skills, and the Foreign & Commonwealth Office), accept liability for any errors, omissions or misleading statements, and no warranty is given or responsibility accepted as to the standing of any individual, firm, company or other organisation mentioned. Published 2010 by UK Trade & Investment. Crown Copyright © UK Trade & Investment Sector briefing: Biotechnology/Pharmaceutical Opportunities in Canada
Posted: 04 October 2010

See more from Pharmaceuticals in Canada

Expert Views    
Biotechnology/Pharmaceutical Opportunities in Canada   By UK Trade & Investment
Life Sciences Sector   By UK Trade & Investment
Presenting the contributor